CAMBRIDGE, Mass. Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has been granted Orphan Disease Designation by the FDA for its drug AU-011 for the treatment of Uveal Melanoma. The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics, which demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions in the US. In addition, the first oral presentation of Aura Biosciences’ pre-clinical research, ‘Evaluating the in vivo efficacy of a first-in-class drug for the treatment of primary uveal melanoma’, was recently delivered by McGill University Health Centre researchers at the ARVO (Association for Research in Vision and Ophthalmology) Annual Meeting.
Conferences
Robert H. Pierce, MD, Chief Scientific Officer of OncoSec Medical, Invited to Present at 11th Annual PEGS Conference in Boston
Preliminary Results Suggest ImmunoPulse™ IL-12 May Generate Increased TILs and CD8+ T-Cell Infiltration in Merkel Cell Carcinoma and Melanoma Patients
Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma
Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, will present new research on its 105F immunomodulatory treatment candidate for melanoma during the 2015 Society of Investigative Dermatology (SID) Annual Meeting, taking place May 6-9, 2015 in Atlanta, GA.
Cabozantinib and Cobimetinib to Be Featured in Fourteen Presentations at 2015 ASCO Annual Meeting
Exelixis, Inc. today announced that the Exelixis-discovered compounds cabozantinib and cobimetinib will be the subjects of fourteen presentations at the upcoming 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held from May 29 to June 2, 2015 in Chicago, Illinois, is expected to draw 30,000 oncology professionals from around the world.